

# Operational Summary

## for the Fiscal Year Ended March 31, 2025

May 13, 2025  
Mitsubishi Chemical Group Corporation

# Table of Contents

Consolidated Financial Statements for FY2024		References 1	
Summary	3	Chemicals Business Major Growth Investment Plan	23
Statements of Operations	4	Divestiture/closure of non-core businesses in Chemicals	24
Sales Revenue and Core Operating Income by Business Segment	5	Core Markets Trends	25
Analysis of Core Operating Income	6	Analysis of Core Operating Income	26
Overview of Business Segments	7	Trends in Core Operating Income by Business Segment	30
Special Items	12	Trends in Ratio of Core Operating Income to Sales Revenue by Business Segment	31
Cash Flows	13	ROIC by Segment in Chemicals Business	32
Statements of Financial Positions	14	Specialty Materials Breakdown by Business Segment	33
Sales Revenue and Core Operating Income by Business Segment [Quarterly Data]	15	Number of Subsidiaries and Affiliates [Historical Data]	34
FY2025 Forecast		Overseas Sales Revenue, and Core Operating Income [Historical Data]	35
Statements of Operations	17	Statements of Operations [Quarterly Data]	36
Progress on “Three disciplined approaches in business operations”	18	Special Items [Quarterly Data]	37
Sales Revenue and Core Operating Income by Business Segment	19	Capital Expenditure, Depreciation & Amortization, R&D Expenses, and Number of Employees by Business Segment	38
Dividend Forecast	20	Trends in Indicators for Profitability and Stability	40
Purchase of Treasury Stock	21	References 2	
		Pharma Segment	Status of Research and Development etc. 44

## List of Abbreviations

FY2025	April 1, 2025 – March 31, 2026
FY2024	April 1, 2024 – March 31, 2025
FY2023	April 1, 2023 – March 31, 2024

MCG	Mitsubishi Chemical Group Corporation
MCC	Mitsubishi Chemical Corporation
MTPC	Mitsubishi Tanabe Pharma Corporation
NSHD	Nippon Sanso Holdings Corporation

## FY2024 Actual

- The business environment during fiscal 2024 generally remained stable, despite some different levels of strength in demand among regions and industries. Display-related sales continued to be strong on the back of the effect of subsidy policy in China, and semiconductor-related sales remained on a moderate recovery path, driven by demand related to generative AI. On the other hand, sales were sluggish in some regions and sectors, such as automotive and food-related markets.
- Core operating income of the chemicals business significantly improved from a ¥11.2 billion loss in the previous fiscal year to a ¥46.9 billion profit. In addition to year-on-year improvement in price gap, chiefly for MMA and Basic Materials & Polymers, sales volume improved overall, despite the recording of one-time impairment loss in Specialty Materials. Looking at the MCG Group on the whole, sales revenue remained virtually unchanged from the previous fiscal year primarily reflecting the effect of the transfer of shares of an affiliate, while core operating income rose 43% year on year.
- Net income attributable to owners of the parent decreased 62% year on year due mainly to the recording of structure reform expenses under special items.

## FY2025 Forecast

- We will continue to rapidly implement initiatives aimed at portfolio transformation and profit improvement based on the “three criteria for business selection” and “three disciplined approaches in business operations” under the guiding principles for our business operations in the New Medium-Term Management Plan 2029.
- Core operating income\* in fiscal 2025 is forecast at ¥265 billion. Core operating income of the chemicals business is expected to increase 78% year on year to ¥76.0 billion on the back of structural reform in the coal business, pricing policy in each business, and the effect of cost reduction efforts.
- Net income attributable to owners of the parent is projected to be ¥145 billion mainly reflecting the recording of proceeds from the transfer of Mitsubishi Tanabe Pharma, despite the posting of structural reform related expenses in tandem with the implementation of management measures. As for dividend forecast, we project a year-end dividend of ¥16 per share and an annual dividend of ¥32 per share.
- In order to utilize approximately ¥510 billion proceeds from the transfer of Mitsubishi Tanabe Pharma to boost shareholder return and increase capital efficiency, we will establish a ¥50 billion facility to purchase treasury stock.

\*As announced on February 7, 2025, MCG has decided on the transfer of Mitsubishi Tanabe Pharma. In the forecast for fiscal 2025, the Pharma business is deemed as a discontinued operation from the beginning of period on the assumption that the transfer will be completed. Therefore, profit from the Pharma business is not included in core operating income forecast for fiscal 2025.

# Consolidated Statements of Operations



	145.3	152.6	7.3	5%
Exchange Rate (¥/\$)				
Naphtha Price (¥/kl)	69,100	75,600	6,500	9%
	(Billions of Yen)			
	FY2023	FY2024	Difference	%
<b>Sales Revenue</b>	4,387.2	<b>4,407.4</b>	<b>20.2</b>	0%
<b>Core Operating Income *1</b>	208.1	<b>298.4</b>	<b>90.3</b>	43%
Special Items	53.7	<b>(101.7)</b>	<b>(155.4)</b>	
<b>Operating Income</b>	261.8	<b>196.7</b>	<b>(65.1)</b>	<b>(25%)</b>
<b>Income before Taxes</b>	240.5	<b>150.7</b>	<b>(89.8)</b>	<b>(37%)</b>
<b>Net Income</b>	178.4	<b>105.6</b>	<b>(72.8)</b>	
<b>Net Income Attributable to Owners of the Parent</b>	119.6	<b>45.0</b>	<b>(74.6)</b>	<b>(62%)</b>
Net Income Attributable to Non-Controlling Interests	58.8	<b>60.6</b>	<b>1.8</b>	
*1 Share of profit of associates and joint ventures included	7.6	<b>8.1</b>	<b>0.5</b>	

Core operating income is calculated as operating income (loss) excluding certain gains and expenses attributable to non-recurring factors (losses incurred by business withdrawal and streamlining, etc.).

# Sales Revenue and Core Operating Income by Business Segment

(Billions of Yen)


	FY2023		FY2024		Difference			
	Sales Revenue	Core Operating Income	Sales Revenue	Core Operating Income	Sales Revenue	%	Core Operating Income	%
<b>Total Consolidated</b>	<b>4,387.2</b>	<b>208.1</b>	<b>4,407.4</b>	<b>298.4</b>	<b>20.2</b>	0%	<b>90.3</b>	43%
<b>Specialty Materials</b>	<b>1,043.8</b>	<b>7.4</b>	<b>1,081.3</b>	<b>25.1</b>	<b>37.5</b>	4%	<b>17.7</b>	239%
Advanced Films & Polymers	459.1	18.3	475.8	35.2	16.7		16.9	
Advanced Solutions	362.9	0.6	355.1	1.4	(7.8)		0.8	
Advanced Composites & Shapes	221.8	(11.5)	250.4	(11.5)	28.6		0.0	
<b>MMA &amp; Derivatives</b>	<b>348.0</b>	<b>5.5</b>	<b>402.1</b>	<b>35.3</b>	<b>54.1</b>	16%	<b>29.8</b>	542%
MMA	261.2	4.1	308.0	32.2	46.8		28.1	
Coating & Additives	86.8	1.4	94.1	3.1	7.3		1.7	
<b>Basic Materials &amp; Polymers</b>	<b>1,106.5</b>	<b>(25.4)</b>	<b>972.4</b>	<b>(15.6)</b>	<b>(134.1)</b>	(12%)	<b>9.8</b>	-
Materials & Polymers	802.8	(6.0)	766.7	12.3	(36.1)		18.3	
Carbon Products	303.7	(19.4)	205.7	(27.9)	(98.0)		(8.5)	
<b>Others</b>	<b>204.8</b>	<b>1.3</b>	<b>190.2</b>	<b>2.1</b>	<b>(14.6)</b>	(7%)	<b>0.8</b>	62%
<b>Chemicals Business</b>	<b>2,703.1</b>	<b>(11.2)</b>	<b>2,646.0</b>	<b>46.9</b>	<b>(57.1)</b>	(2%)	<b>58.1</b>	-
Pharma	437.2	56.3	460.3	65.4	23.1	5%	9.1	16%
Industrial Gases	1,246.9	163.0	1,301.1	186.1	54.2	4%	23.1	14%
<b>Group Business</b>	<b>1,684.1</b>	<b>219.3</b>	<b>1,761.4</b>	<b>251.5</b>	<b>77.3</b>	5%	<b>32.2</b>	15%

[Inventory valuation gain/loss]	FY2023	FY2024	Difference
Advanced Films & Polymers	0.4	0.2	(0.2)
Materials & Polymers	3.6	2.0	(1.6)
Carbon Products	2.5	(9.4)	(11.9)
Total	6.5	(7.2)	(13.7)

- From Q1 FY2024, the current financial reporting segments has been reclassified into Specialty Materials, Industrial Gases, Pharma, MMA & Derivatives, Basic Materials & Polymers, and Others. In addition, the company is reclassifying the managing segments for some of its businesses. Accordingly, for purposes of comparison, we are restated the results for FY2023.
- Breakdown figures of segment are approximation for reference purpose only.
- Based on careful examination of results for FY2023 of new business segment basis, the figures has been changed partially from those announced on May 15,2024.
- In line with the New Medium-Term Management Plan 2029 announced in November 2024, the order of reporting segments has been changed from the third quarter of FY2024.

# Analysis of Core Operating Income

(Billions of Yen) **+90.3 Billion Yen**




	FY2023	FY2024	Difference	(Billions of Yen)			
				Price	Volume	Cost reduction	Others *1
<b>Total Consolidated</b>	208.1	<b>298.4</b>	<b>90.3</b>	<b>54.0</b>	<b>21.0</b>	<b>60.1</b>	<b>(44.8)</b>
Specialty Materials	7.4	<b>25.1</b>	<b>17.7</b>	7.9	20.2	8.1	<b>(18.5)</b>
MMA & Derivatives	5.5	<b>35.3</b>	<b>29.8</b>	28.2	2.8	3.3	<b>(4.5)</b>
Basic Materials & Polymers	<b>(25.4)</b>	<b>(15.6)</b>	<b>9.8</b>	20.6	<b>(2.5)</b>	6.7	<b>(15.0)</b>
Others	1.3	<b>2.1</b>	<b>0.8</b>	0.9	<b>(0.8)</b>	3.6	<b>(2.9)</b>
Chemicals Business	<b>(11.2)</b>	<b>46.9</b>	<b>58.1</b>	57.6	19.7	21.7	<b>(40.9)</b>
Pharma	56.3	<b>65.4</b>	<b>9.1</b>	<b>(0.1)</b>	8.5	2.7	<b>(2.0)</b>
Industrial Gases	163.0	<b>186.1</b>	<b>23.1</b>	<b>(3.5)</b>	<b>(7.2)</b>	35.7	<b>(1.9)</b>
Group Business	219.3	<b>251.5</b>	<b>32.2</b>	<b>(3.6)</b>	1.3	38.4	<b>(3.9)</b>

\*1 Items included are impacts from differences of inventory valuation gain/loss (13.7) billion yen and differences of share of profit of associates and joint ventures +0.5 billion yen, etc.

Changes in exchange rates	11.7	14.6	-	-	<b>(2.9)</b>
Changes in foreign currency translation included in above	9.2				

# Analysis of Core Operating Income Specialty Materials Segment



## Advanced Films & Polymers +16.9

- Price** (+) Improvement in price gap for various products as retaining and improving selling price
- (-)** Deterioration in price gap for barrier packaging, etc.
- Volume** (+) Increase in sales due to a rise in demand for displays and other applications

## Advanced Solutions +0.8

- Price** (+) Improvement in price gap for various products as retaining and improving selling price
- Volume** (+) Increase in sales due to a moderate recovery in demand related to semiconductors

## Advanced Composites & Shapes ±0

- Price** (+) Deterioration in price gap due to the change in sales composition of carbon fibers
- Volume** (+) Increase in sales due to a moderate recovery in demand for high performance engineering plastics
- (-)** Decline in sales owing to intensified competitions for some carbon fiber applications


## \* Cost reduction, Others

- Cost reduction** (+) Business structure reform, optimization of procurement, productivity enhancement, etc.
- Others** (-) Impairment of production equipment and intangible assets related to Gelest, Inc. (12.9)bn  
Increase in labor cost and other fixed expenses, increase in amortization of intangible assets in tandem with acquisition of CPC as a consolidated subsidiary, etc.

# Analysis of Core Operating Income MMA & Derivatives Segment

**+29.8 Billion Yen**

(Billions of Yen)



## MMA +28.1

Price

(+) Improvement in price gap due to a rise in market prices chiefly for MMA monomer

Cost reduction

(+) Decline in fixed expenses as a result of the discontinuation of MMA production by the ACH process at Hiroshima Plant

## Coating & Additives +1.7

Price Volume


(+) Improvement in price gap and a rise in demand for paints / adhesives / inks / additives

# Analysis of Core Operating Income

## Basic Materials & Polymers Segment

**+9.8 Billion Yen**

(Billions of Yen)



### Materials & Polymers + 18.3

Price

(+) Discrepancy in the timing for revision to polyolefin prices

Volume

(-) Decline in sales due to diminished demand for various products

Cost  
reduction

(+) Optimization of equipment procurement and maintenance cost

### Carbon Products (8.5)

Price

(+) Improvement in price gap for cokes due mainly to a fall in raw material prices


Others

(-) Deterioration in inventory valuation in tandem with a decline in raw material prices

# Analysis of Core Operating Income Pharma Segment

**+9.1 Billion Yen**

(Billions of Yen)



## Pharma + 9.1

### Price

- (+) Forex impact on overseas ethical pharmaceuticals, etc.
- (-) National Health Insurance drug price revision for domestic ethical pharmaceuticals, etc.


### Volume

- (+) In North America, sales grew for RADICAVA ORS®, a therapy to treat ALS
- (+) Growth in sales of Mounjaro
- (+) Steady launch of GOBIK combination vaccine for five diseases

# Analysis of Core Operating Income Industrial Gases Segment

**+23.1 Billion Yen**

(Billions of Yen)



## Industrial Gases +23.1

### Volume

(-) Decline in the sales volume of products other than air-separated gases in tandem with sluggish gas demand in the U.S.

### Cost reduction

(+) Productivity improvement activities, include the use of DX and optimization of plant operations

# Consolidated Special Items

(Billions of Yen)

	FY2023	FY2024	Difference
<b>Total Special Items</b>	53.7	<b>(101.7)</b>	<b>(155.4)</b>
Gain on sales of shares of subsidiaries and associates	36.5	<b>11.3</b>	<b>(25.2)</b>
Gain on sale of property, plant and equipment	1.6	<b>9.7</b>	<b>8.1</b>
Impairment loss	<b>(23.8)</b>	<b>(76.6)</b>	<b>(52.8)</b>
Special retirement expenses	<b>(2.0)</b>	<b>(22.1)</b>	<b>(20.1)</b>
Loss on sale and disposal of fixed assets	<b>(9.7)</b>	<b>(15.2)</b>	<b>(5.5)</b>
Cancellation penalty	<b>(0.3)</b>	<b>(3.5)</b>	<b>(3.2)</b>
Loss on sales of shares of subsidiaries and associates	<b>(0.1)</b>	<b>(3.2)</b>	<b>(3.1)</b>
Others	51.5	<b>(2.1)</b>	<b>(53.6)</b>

# Consolidated Cash Flows

	FY2023	FY2024
<b>Net cash provided by (used in) operating activities</b>	<b>465.1</b>	<b>552.8</b>
Income before taxes	240.5	150.7
Depreciation and amortization	275.4	275.9
Change in operating receivables/payables	(16.8)	30.7
Change in Inventories	30.3	13.4
Others	(64.3)	82.1
<b>Net cash provided by (used in) investment activities</b>	<b>(246.1)</b>	<b>(275.4)</b>
Capital expenditure	(274.5)	(325.0)
Sale of assets	72.3	54.0
Investment and loans receivable, etc.	(43.9)	(4.4)
<b>Free cash flow</b>	<b>219.1</b>	<b>277.4</b>

(Billions of Yen)

	FY2023	FY2024
<b>Net cash provided by (used in) financing activities</b>	<b>(241.7)</b>	<b>(246.7)</b>
Interest bearing debts	(166.6)	(182.9)
Dividends, etc.	(75.1)	(63.8)
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(22.7)</b>	<b>30.7</b>
Effect of exchange rate changes and changes in scope of consolidation	20.4	0.5
<b>Total</b>	<b>(2.3)</b>	<b>31.2</b>

# Consolidated Statements of Financial Positions

(Billions of Yen)

	Mar.31.2024	Mar.31.2025	Difference
Cash & cash equivalents	294.9	326.1	31.2
Trade receivables	852.4	764.8	(87.6)
Inventories	799.2	759.4	(39.8)
Others	245.1	211.3	(33.8)
<b>Current assets</b>	<b>2,191.6</b>	<b>2,061.6</b>	<b>(130.0)</b>
Fixed assets	2,524.4	2,446.5	(77.9)
Goodwill	832.9	827.6	(5.3)
Investments & Other	555.6	558.9	3.3
<b>Non-current assets</b>	<b>3,912.9</b>	<b>3,833.0</b>	<b>(79.9)</b>
<b>Total assets</b>	<b>6,104.5</b>	<b>5,894.6</b>	<b>(209.9)</b>

(Billions of Yen)

	Mar.31.2024	Mar.31.2025	Difference
Interest-bearing debt	2,338.2	2,178.5	(159.7)
Trade payables	501.5	424.6	(76.9)
Others	989.3	1,006.9	17.6
<b>Liabilities</b>	<b>3,829.0</b>	<b>3,610.0</b>	<b>(219.0)</b>
Share capitals, Retained earnings, etc.,	1,502.9	1,512.4	9.5
Other components of equity	260.6	228.2	(32.4)
<b>Equity attributable to owners of the parent</b>	<b>1,763.5</b>	<b>1,740.6</b>	<b>(22.9)</b>
Non-controlling interests	512.0	544.0	32.0
<b>Equity</b>	<b>2,275.5</b>	<b>2,284.6</b>	<b>9.1</b>
<b>Total liabilities &amp; equity</b>	<b>6,104.5</b>	<b>5,894.6</b>	<b>(209.9)</b>
Net Interest-bearing debt *1	2,043.3	1,852.3	(191.0)
Net D/E ratio	1.16	1.06	(0.10)
ROE *2	7.2%	2.6%	(4.6%)

\*1 Net interest-bearing debt (End of Mar.31, 2025)

= interest-bearing debt (2,178.5billion yen)

- {cash and cash equivalents (326.1billion yen) + investments of surplus funds-}

Note : Interest-bearing debt includes lease obligations.

\*2 Ratio of net income attributable to owners of the parent.

# Sales Revenue and Core Operating Income by Business Segment [Quarterly Data]

(Billions of Yen)

		FY2023					FY2024				
		1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total
<b>Total Consolidated</b>	Sales Revenue	1,061.2	1,088.7	1,095.2	1,142.1	4,387.2	1,129.4	1,112.7	1,089.4	1,075.9	4,407.4
	<b>Core Operating Income</b>	<b>50.8</b>	<b>68.8</b>	<b>64.3</b>	<b>24.2</b>	<b>208.1</b>	<b>82.6</b>	<b>89.8</b>	<b>74.8</b>	<b>51.2</b>	<b>298.4</b>
<b>Specialty Materials</b>	Sales Revenue	262.6	257.6	256.7	266.9	1,043.8	276.9	265.9	270.0	268.5	1,081.3
	<b>Core Operating Income</b>	<b>9.9</b>	<b>8.9</b>	<b>0.6</b>	<b>(12.0)</b>	<b>7.4</b>	<b>11.5</b>	<b>13.0</b>	<b>9.9</b>	<b>(9.3)</b>	<b>25.1</b>
Advanced Films & Polymers	Sales Revenue	118.1	115.8	113.6	111.6	459.1	120.4	118.8	119.2	117.4	475.8
	<b>Core Operating Income</b>	<b>8.6</b>	<b>8.0</b>	<b>4.2</b>	<b>(2.5)</b>	<b>18.3</b>	<b>9.2</b>	<b>10.3</b>	<b>10.0</b>	<b>5.7</b>	<b>35.2</b>
Advanced Solutions	Sales Revenue	88.7	88.8	92.6	92.8	362.9	88.3	86.9	91.8	88.1	355.1
	<b>Core Operating Income</b>	<b>0.5</b>	<b>2.3</b>	<b>0.4</b>	<b>(2.6)</b>	<b>0.6</b>	<b>3.1</b>	<b>4.1</b>	<b>3.5</b>	<b>(9.3)</b>	<b>1.4</b>
Advanced Composites & Shapes	Sales Revenue	55.8	53.0	50.5	62.5	221.8	68.2	60.2	59.0	63.0	250.4
	<b>Core Operating Income</b>	<b>0.8</b>	<b>(1.4)</b>	<b>(4.0)</b>	<b>(6.9)</b>	<b>(11.5)</b>	<b>(0.8)</b>	<b>(1.4)</b>	<b>(3.6)</b>	<b>(5.7)</b>	<b>(11.5)</b>
<b>MMA &amp; Derivatives</b>	Sales Revenue	84.4	86.4	85.8	91.4	348.0	108.1	108.5	92.3	93.2	402.1
	<b>Core Operating Income</b>	<b>0.1</b>	<b>3.1</b>	<b>(0.6)</b>	<b>2.9</b>	<b>5.5</b>	<b>10.9</b>	<b>15.8</b>	<b>5.9</b>	<b>2.7</b>	<b>35.3</b>
MMA	Sales Revenue	63.3	64.6	63.7	69.6	261.2	84.3	85.1	69.4	69.2	308.0
	<b>Core Operating Income</b>	<b>(0.1)</b>	<b>2.7</b>	<b>(0.9)</b>	<b>2.4</b>	<b>4.1</b>	<b>9.8</b>	<b>14.9</b>	<b>5.6</b>	<b>1.9</b>	<b>32.2</b>
Coating & Additives	Sales Revenue	21.1	21.8	22.1	21.8	86.8	23.8	23.4	22.9	24.0	94.1
	<b>Core Operating Income</b>	<b>0.2</b>	<b>0.4</b>	<b>0.3</b>	<b>0.5</b>	<b>1.4</b>	<b>1.1</b>	<b>0.9</b>	<b>0.3</b>	<b>0.8</b>	<b>3.1</b>
<b>Basic Materials &amp; Polymers</b>	Sales Revenue	264.9	274.3	283.1	284.2	1,106.5	268.4	263.6	241.8	198.6	972.4
	<b>Core Operating Income</b>	<b>(9.6)</b>	<b>(6.1)</b>	<b>0.8</b>	<b>(10.5)</b>	<b>(25.4)</b>	<b>(7.2)</b>	<b>(4.1)</b>	<b>(0.8)</b>	<b>(3.5)</b>	<b>(15.6)</b>
Materials & Polymers	Sales Revenue	179.7	202.9	211.7	208.5	802.8	193.4	196.5	205.0	171.8	766.7
	<b>Core Operating Income</b>	<b>(6.0)</b>	<b>0.4</b>	<b>3.2</b>	<b>(3.6)</b>	<b>(6.0)</b>	<b>1.1</b>	<b>3.9</b>	<b>4.2</b>	<b>3.1</b>	<b>12.3</b>
Carbon Products	Sales Revenue	85.2	71.4	71.4	75.7	303.7	75.0	67.1	36.8	26.8	205.7
	<b>Core Operating Income</b>	<b>(3.6)</b>	<b>(6.5)</b>	<b>(2.4)</b>	<b>(6.9)</b>	<b>(19.4)</b>	<b>(8.3)</b>	<b>(8.0)</b>	<b>(5.0)</b>	<b>(6.6)</b>	<b>(27.9)</b>
<b>Others</b>	Sales Revenue	40.6	51.6	36.8	75.8	204.8	36.0	42.8	42.3	69.1	190.2
	<b>Core Operating Income</b>	<b>0.3</b>	<b>0.3</b>	<b>(1.7)</b>	<b>2.4</b>	<b>1.3</b>	<b>1.5</b>	<b>(2.3)</b>	<b>1.1</b>	<b>1.8</b>	<b>2.1</b>
<b>Chemicals Business</b>	Sales Revenue	652.5	669.9	662.4	718.3	2,703.1	689.4	680.8	646.4	629.4	2,646.0
	<b>Core Operating Income</b>	<b>0.7</b>	<b>6.2</b>	<b>(0.9)</b>	<b>(17.2)</b>	<b>(11.2)</b>	<b>16.7</b>	<b>22.4</b>	<b>16.1</b>	<b>(8.3)</b>	<b>46.9</b>
Pharma	Sales Revenue	101.9	117.4	118.6	99.3	437.2	112.5	120.0	116.6	111.2	460.3
	<b>Core Operating Income</b>	<b>10.0</b>	<b>22.4</b>	<b>23.0</b>	<b>0.9</b>	<b>56.3</b>	<b>18.5</b>	<b>22.9</b>	<b>13.1</b>	<b>10.9</b>	<b>65.4</b>
Industrial Gases	Sales Revenue	306.8	301.4	314.2	324.5	1,246.9	327.5	311.9	326.4	335.3	1,301.1
	<b>Core Operating Income</b>	<b>40.1</b>	<b>40.2</b>	<b>42.2</b>	<b>40.5</b>	<b>163.0</b>	<b>47.4</b>	<b>44.5</b>	<b>45.6</b>	<b>48.6</b>	<b>186.1</b>
<b>Group Business</b>	Sales Revenue	408.7	418.8	432.8	423.8	1,684.1	440.0	431.9	443.0	446.5	1,761.4
	<b>Core Operating Income</b>	<b>50.1</b>	<b>62.6</b>	<b>65.2</b>	<b>41.4</b>	<b>219.3</b>	<b>65.9</b>	<b>67.4</b>	<b>58.7</b>	<b>59.5</b>	<b>251.5</b>

- From Q1 FY2024, the current financial reporting segments has been reclassified into Specialty Materials, Industrial Gases, Pharma, MMA & Derivatives, Basic Materials & Polymers, and Others. In addition, the company is reclassifying the managing segments for some of its businesses. Accordingly, for purposes of comparison, we are restated the results for FY2023.
- Breakdown figures of segment are approximation for reference purpose only.
- Based on careful examination of results for FY2023 of new business segment basis, the figures has been changed partially from those announced on May 15,2024.
- In line with the New Medium-Term Management Plan 2029 announced in November 2024, the order of reporting segments has been changed from the third quarter of FY2024.

# Consolidated Financial Results Forecasts for FY2025

# Consolidated Statements of Operations

Exchange Rate (¥/\$)	152.6	140.0	140.0	140.0	(12.6)
Naphtha Price (¥/kl)	75,600	65,000	65,000	65,000	(10,600)

	FY2024 Actual	FY2025 Forecast		Difference	%
		1H	2H		
<b>Sales Revenue</b>	3,947.6	1,803.0	1,937.0	<b>(207.6)</b>	<b>(5%)</b>
<b>Core Operating Income</b>	228.8	121.0	144.0	<b>36.2</b>	16%
Special Items	(88.1)	(10.0)	(53.0)	<b>25.1</b>	
<b>Operating Income</b>	140.7	111.0	91.0	<b>61.3</b>	44%
Financial Income/Expenses	(42.3)	(17.0)	(20.0)	<b>5.3</b>	
<b>Income before Taxes</b>	98.4	94.0	71.0	<b>66.6</b>	68%
Income Taxes	(40.9)	(25.0)	(21.0)	<b>(5.1)</b>	
<b>Net Income from Continuing Operations</b>	57.5	69.0	50.0	<b>61.5</b>	107%
Net Income from Discontinued Operations	48.2	94.0	0.0	<b>45.8</b>	
<b>Net Income</b>	105.6	163.0	50.0	<b>107.4</b>	102%
<b>Net Income Attributable to Owners of the Parent</b>	45.0	130.0	15.0	<b>100.0</b>	222%
Net Income Attributable to Non-Controlling Interests	60.6	33.0	35.0	<b>7.4</b>	


(Billions of Yen)

# Progress on “Three disciplined approaches in business operations”

Pricing policy

Investment decision making

Asset optimization



# Sales Revenue and Core Operating Income by Business Segment


(Billions of Yen)

		FY2024 Actual	1H	2H	FY2025 Forecast	Difference
<b>Total Consolidated</b>	Sales Revenue	3,947.6	1,803.0	1,937.0	3,740.0	(207.6)
	<b>Core Operating Income</b>	<b>228.8</b>	<b>121.0</b>	<b>144.0</b>	<b>265.0</b>	<b>36.2</b>
<b>Specialty Materials</b>	Sales Revenue	1,073.3	550.0	570.0	1,120.0	46.7
	<b>Core Operating Income</b>	<b>25.1</b>	<b>21.0</b>	<b>25.0</b>	<b>46.0</b>	<b>20.9</b>
Advanced Films & Polymers	Sales Revenue	472.7	238.0	247.0	485.0	12.3
	<b>Core Operating Income</b>	<b>35.2</b>	<b>16.0</b>	<b>16.0</b>	<b>32.0</b>	<b>(3.2)</b>
Advanced Solutions	Sales Revenue	350.3	178.0	182.0	360.0	9.7
	<b>Core Operating Income</b>	<b>1.4</b>	<b>6.0</b>	<b>7.0</b>	<b>13.0</b>	<b>11.6</b>
Advanced Composites & Shapes	Sales Revenue	250.3	134.0	141.0	275.0	24.7
	<b>Core Operating Income</b>	<b>(11.5)</b>	<b>(1.0)</b>	<b>2.0</b>	<b>1.0</b>	<b>12.5</b>
<b>MMA &amp; Derivatives</b>	Sales Revenue	419.1	141.0	179.0	320.0	(99.1)
	<b>Core Operating Income</b>	<b>35.7</b>	<b>9.0</b>	<b>12.0</b>	<b>21.0</b>	<b>(14.7)</b>
MMA	Sales Revenue	307.5	94.0	131.0	225.0	(82.5)
	<b>Core Operating Income</b>	<b>32.2</b>	<b>8.0</b>	<b>11.0</b>	<b>19.0</b>	<b>(13.2)</b>
Coating & Additives	Sales Revenue	111.6	47.0	48.0	95.0	(16.6)
	<b>Core Operating Income</b>	<b>3.5</b>	<b>1.0</b>	<b>1.0</b>	<b>2.0</b>	<b>(1.5)</b>
<b>Basic Materials &amp; Polymers</b>	Sales Revenue	985.4	410.0	443.0	853.0	(132.4)
	<b>Core Operating Income</b>	<b>(15.1)</b>	<b>2.0</b>	<b>8.0</b>	<b>10.0</b>	<b>25.1</b>
Materials & Polymers	Sales Revenue	776.4	362.0	388.0	750.0	(26.4)
	<b>Core Operating Income</b>	<b>12.4</b>	<b>3.0</b>	<b>6.0</b>	<b>9.0</b>	<b>(3.4)</b>
Carbon Products	Sales Revenue	209.0	48.0	55.0	103.0	(106.0)
	<b>Core Operating Income</b>	<b>(27.5)</b>	<b>(1.0)</b>	<b>2.0</b>	<b>1.0</b>	<b>28.5</b>
<b>Others</b>	Sales Revenue	168.7	69.0	96.0	165.0	(3.7)
	<b>Core Operating Income</b>	<b>(3.0)</b>	<b>(3.0)</b>	<b>2.0</b>	<b>(1.0)</b>	<b>2.0</b>
<b>Chemicals Business</b>	Sales Revenue	2,646.5	1,170.0	1,288.0	2,458.0	(188.5)
	<b>Core Operating Income</b>	<b>42.7</b>	<b>29.0</b>	<b>47.0</b>	<b>76.0</b>	<b>33.3</b>
<b>Industrial Gases</b>	Sales Revenue	1,301.1	633.0	649.0	1,282.0	(19.1)
	<b>Core Operating Income</b>	<b>186.1</b>	<b>92.0</b>	<b>97.0</b>	<b>189.0</b>	<b>2.9</b>

\* Breakdown figures of segment are approximation for reference purpose only.


# Dividend Forecast

- MCG’s basic policy for shareholder returns is to enhance its shareholder value by increasing corporate value.
- While keeping an eye on increasing retained earnings that will fund its future business activities, MCG will aim to maintain a target dividend payout ratio of 35% under the “New Medium-Term Management Plan 2029,” with a potential dividend increase based on further profit growth.
- The expected fiscal year-end dividend per share for FY2024 is 16 yen, which is the same as the previously announced forecast. This is scheduled to be approved at the Board of Directors meeting, scheduled for May 20, 2025.
- We forecast an interim and fiscal year-end cash dividend per share in FY2025 of 16 yen, which is equivalent to the fiscal year-end dividend for FY2024. Accordingly, the expected full-fiscal year dividend for FY2025 is 32 yen.



# Purchase of Treasury Stock

Utilize approximately ¥510 billion of proceeds from the transfer of Mitsubishi Tanabe Pharma to establish a ¥50 billion facility for the purchase of treasury stock



\* Stable supply platform for green chemicals, Eco-conscious mobility, Enable advanced data processing and telecommunications, Food quality preservation and Technology and equipment for new therapeutics.

# References 1


# Chemicals Business Major Growth Investment Plan

## FY25 FY26 FY27 FY28

Polyester film capacity increase Germany



Lithomax™ capacity increase (Photosensitive polymer for photoresists used in semiconductor circuit formation) Japan




Strengthen semiconductor precision cleaning business Japan



Optical Film for Polarizers "OPL FILM™" capacity increase Japan



Mitsubishi Synthetic Quartz Powder capacity increase for semiconductors Japan



Carbon fiber composite materials expansion of large press molding machine Italy



Natural anode materials for Automotive lithium-ion battery capacity increase Japan



Soarnol™ capacity increase UK




Emulsifier capacity increase Japan



# Divestiture/closure of non-core businesses in Chemicals


## Accelerate liquidation and divestiture of non-core businesses



# Core Markets Trends


Market	Key Products	4Q FY2024 Summary	Forecast for 1Q FY2025 Onward
<b>EV/Mobility</b>	<b>Electrolytes, Anode materials</b> <b>Carbon fiber, Composites</b> <b>Polymer, Compounds</b>	Demand growth slowed, except for some regions, due to a negative impact of a decline in production in Japan as well as Europe and the U.S.	Global automobile production expected to weaken in 2025 due to the effect of the U.S. trade policy among other factors. In the medium/long-term, moderate growth to continue in general
<b>Semiconductors</b>	<b>Synthetic silica</b> <b>High functional cleaning agents</b> <b>Precision cleaning</b> <b>Specialty epoxy resins</b> <b>Photolithography materials</b> <b>Semiconductor manufacturing equipment parts</b>	While AI-related sales were favorable, sales related to industrial machinery, consumer equipment (home appliances) and automobile applications remained weak	Sales related to AI are expected to continue to be strong. Sales related to industrial machinery, consumer equipment (home appliances) and automobile applications to recover moderately. In the medium/long-term, forecast ongoing market growth owing to further expansion in demand
<b>Electronics</b>	<b>Optical films</b> <b>Display related materials</b>	High operations of panel manufacturers continued on the back of the effect of subsidy policy in China and a rise in demand looking ahead of the U.S. tariff hikes	Operations of panel manufacturers are expected to slow down after Q2 FY2025 Robust demand to continue in the medium to long term in tandem with the trend toward larger TVs
<b>Medical</b>	<b>Resins / shapes for implant</b>	Remained brisk globally (Inventory adjustments for some products also came to an end)	Market growth is expected to continue in the medium to long term due to the increase in the aging population and the prevalence of lifestyle-related diseases and chronic diseases
<b>Food</b>	<b>Barrier Films and Resins</b> <b>Emulsifiers</b>	Food packaging market remained sluggish globally due mainly to the impact of inflation	Global demand in the food packaging material market to recover moderately In the medium/long term, anticipate an expansion in demand underscored mainly by a reduction in food loss

# Analysis of Core Operating Income (3Q→4Q)




\*AF&P= Advanced Films & Polymers, AS=Advanced Solutions, AC&S=Advanced Composites & Shapes, C&A=Coating & Additives, M&P=Materials & Polymers

# Analysis of Core Operating Income (FY24/2H→FY25/1H)




\*AF&P= Advanced Films & Polymers, AS=Advanced Solutions, AC&S=Advanced Composites & Shapes, C&A=Coating & Additives, M&P=Materials & Polymers

# Analysis of Core Operating Income (FY25/1H→FY25/2H)



\*AF&P= Advanced Films & Polymers, AS=Advanced Solutions, AC&S=Advanced Composites & Shapes, C&A=Coating & Additives, M&P=Materials & Polymers

# Analysis of Core Operating Income (FY24→FY25)



\*AF&P= Advanced Films & Polymers, AS=Advanced Solutions, AC&S=Advanced Composites & Shapes, C&A=Coating & Additives, M&P=Materials & Polymers

# Trends in Core Operating Income by Business Segment

(Billions of Yen)

	FY2024 Actual	FY2025 Forecast	FY2029 Target
<b>Total Consolidated</b>	<b>228.8</b>	<b>265.0</b>	<b>460.0</b>
<b>Specialty Materials</b>	<b>25.1</b>	<b>46.0</b>	<b>144.0</b>
Advanced Films & Polymers	35.2	32.0	56.0
Advanced Solutions	1.4	13.0	46.0
Advanced Composites & Shapes	(11.5)	1.0	42.0
<b>MMA &amp; Derivatives</b>	<b>35.7</b>	<b>21.0</b>	<b>54.0</b>
MMA	32.2	19.0	45.0
Coating & Additives	3.5	2.0	9.0
<b>Basic Materials &amp; Polymers</b>	<b>(15.1)</b>	<b>10.0</b>	<b>44.0</b>
Materials & Polymers	12.4	9.0	41.0
Carbon Products	(27.5)	1.0	4.0
<b>Others</b>	<b>(3.0)</b>	<b>(1.0)</b>	<b>(6.0)</b>
<b>Chemicals Business</b>	<b>42.7</b>	<b>76.0</b>	<b>236.0</b>
<b>Industrial Gases</b>	<b>186.1</b>	<b>189.0</b>	<b>224.0</b>

- With regard to Industrial Gases Business, Mitsubishi Chemical Group Corporation has made its own estimates based on "NS Vision 2026", which was formulated by Nippon Sanso Holdings Corporation in 2022, and incorporates the effects of continuous demand growth, price management, productivity improvements, etc.

# Trends in Ratio of Core Operating Income to Sales Revenue by Business Segment

	FY2024 Actual	FY2025 Forecast	FY2029 Target
<b>Total Consolidated</b>	<b>6%</b>	<b>7%</b>	<b>10%</b>
<b>Specialty Materials</b>	<b>2%</b>	<b>4%</b>	<b>10%</b>
Advanced Films & Polymers	7%	7%	10%
Advanced Solutions	0%	4%	9%
Advanced Composites & Shapes	(5%)	0%	11%
<b>MMA &amp; Derivatives</b>	<b>9%</b>	<b>7%</b>	<b>12%</b>
MMA	10%	8%	14%
Coating & Additives	3%	2%	8%
<b>Basic Materials &amp; Polymers</b>	<b>(2%)</b>	<b>1%</b>	<b>4%</b>
Materials & Polymers	2%	1%	5%
Carbon Products	(13%)	1%	3%
<b>Others</b>	<b>(2%)</b>	<b>(1%)</b>	<b>(3%)</b>
<b>Chemicals Business</b>	<b>2%</b>	<b>3%</b>	<b>8%</b>
<b>Industrial Gases</b>	<b>14%</b>	<b>15%</b>	<b>15%</b>

- With regard to Industrial Gases Business, Mitsubishi Chemical Group Corporation has made its own estimates based on “NS Vision 2026”, which was formulated by Nippon Sanso Holdings Corporation in 2022, and incorporates the effects of continuous demand growth, price management, productivity improvements, etc.

# ROIC by Segment in Chemicals Business

	FY2024 Actual	FY2025 Forecast	FY2029 Target
<b>Chemicals Business</b>	<b>1.7%</b>	<b>2.1%</b>	<b>6.7%</b>
<b>Specialty Materials</b>	<b>1.9%</b>	<b>3.3%</b>	<b>9.5%</b>
Advanced Films & Polymers	6.6%	5.8%	10.1%
Advanced Solutions	0.4%	3.2%	10.0%
Advanced Composite & Shapes	(2.5%)	0.2%	8.5%
<b>MMA &amp; Derivatives</b>	<b>6.7%</b>	<b>4.1%</b>	<b>9.6%</b>
MMA	7.7%	4.7%	9.8%
Coating & Additives	2.9%	2.2%	9.1%
<b>Basic Materials &amp; Polymers</b>	<b>(2.1%)</b>	<b>1.5%</b>	<b>7.1%</b>
Materials & Polymers	2.1%	1.6%	7.7%
Carbon	(20.1%)	1.4%	3.6%

• Breakdown figures of segment are approximation for reference purpose only.

# Specialty Materials Breakdown by Business Segment

(Billions of Yen)

		FY2023 Actual					FY2024 Actual					FY2029 Target	Ratio of Core Operating Income to Sales Revenue		
		1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	Total	FY2023	FY2024	FY2029
													Total	Total	Total
<b>Specialty Materials</b>	Sales Revenue	262.6	257.6	256.7	266.9	1,043.8	276.9	265.9	270.0	268.5	1,081.3	1,408.0	-	-	-
	<b>Core Operating Income</b>	<b>9.9</b>	<b>8.9</b>	<b>0.6</b>	<b>(12.0)</b>	<b>7.4</b>	<b>11.5</b>	<b>13.0</b>	<b>9.9</b>	<b>(9.3)</b>	<b>25.1</b>	<b>144.0</b>	<b>1%</b>	<b>2%</b>	<b>10%</b>
<b>Advanced Films &amp; Polymers</b>	Sales Revenue	118.1	115.8	113.6	111.6	459.1	120.4	118.8	119.2	117.4	475.8	534.0	-	-	-
	<b>Core Operating Income</b>	<b>8.6</b>	<b>8.0</b>	<b>4.2</b>	<b>(2.5)</b>	<b>18.3</b>	<b>9.2</b>	<b>10.3</b>	<b>10.0</b>	<b>5.7</b>	<b>35.2</b>	<b>56.0</b>	<b>4%</b>	<b>7%</b>	<b>10%</b>
Films	Sales Revenue	66.1	66.8	65.4	64.6	262.8	72.9	72.3	73.6	71.2	290.0	310.0	-	-	-
	<b>Core Operating Income</b>	<b>1.9</b>	<b>1.6</b>	<b>2.1</b>	<b>(1.7)</b>	<b>3.9</b>	<b>5.7</b>	<b>4.6</b>	<b>4.5</b>	<b>3.4</b>	<b>18.2</b>	<b>30.0</b>	<b>1%</b>	<b>6%</b>	<b>10%</b>
Polymers	Sales Revenue	44.5	42.1	41.0	41.1	168.6	43.7	42.5	42.1	43.4	171.7	221.0	-	-	-
	<b>Core Operating Income</b>	<b>7.8</b>	<b>6.7</b>	<b>4.4</b>	<b>1.6</b>	<b>20.4</b>	<b>4.3</b>	<b>6.2</b>	<b>6.9</b>	<b>5.4</b>	<b>22.8</b>	<b>31.0</b>	<b>12%</b>	<b>13%</b>	<b>14%</b>
<b>Advanced Solutions</b>	Sales Revenue	88.7	88.8	92.6	92.8	362.9	88.3	86.9	91.8	88.1	355.1	502.0	-	-	-
	<b>Core Operating Income</b>	<b>0.5</b>	<b>2.3</b>	<b>0.4</b>	<b>(2.6)</b>	<b>0.6</b>	<b>3.1</b>	<b>4.1</b>	<b>3.5</b>	<b>(9.3)</b>	<b>1.4</b>	<b>46.0</b>	<b>0%</b>	<b>0%</b>	<b>9%</b>
Semiconductor	Sales Revenue	15.4	14.8	15.2	17.4	62.8	17.8	17.2	18.5	18.2	71.7	105.0	-	-	-
	<b>Core Operating Income</b>	<b>0.2</b>	<b>(0.4)</b>	<b>0.1</b>	<b>(0.2)</b>	<b>(0.2)</b>	<b>0.8</b>	<b>0.6</b>	<b>0.4</b>	<b>1.7</b>	<b>3.5</b>	<b>17.0</b>	<b>0%</b>	<b>5%</b>	<b>16%</b>
Battery & Electronics	Sales Revenue	22.3	22.2	22.3	20.9	87.7	21.8	18.9	18.8	17.3	76.8	155.0	-	-	-
	<b>Core Operating Income</b>	<b>0.2</b>	<b>0.2</b>	<b>(0.3)</b>	<b>(0.3)</b>	<b>(0.2)</b>	<b>1.8</b>	<b>1.1</b>	<b>0.5</b>	<b>1.0</b>	<b>4.4</b>	<b>14.0</b>	<b>0%</b>	<b>6%</b>	<b>9%</b>
Water & Environment Solutions	Sales Revenue	12.6	13.4	13.7	14.6	54.3	12.8	14.8	15.2	14.5	57.3	64.0	-	-	-
	<b>Core Operating Income</b>	<b>1.4</b>	<b>1.9</b>	<b>1.0</b>	<b>0.5</b>	<b>4.9</b>	<b>1.3</b>	<b>1.8</b>	<b>1.1</b>	<b>1.5</b>	<b>5.7</b>	<b>7.0</b>	<b>9%</b>	<b>10%</b>	<b>11%</b>
Life Solutions	Sales Revenue	11.6	12.1	13.0	13.4	50.2	12.8	13.2	13.8	13.1	52.9	67.0	-	-	-
	<b>Core Operating Income</b>	<b>0.2</b>	<b>1.4</b>	<b>0.6</b>	<b>(0.3)</b>	<b>2.0</b>	<b>(0.4)</b>	<b>0.4</b>	<b>0.7</b>	<b>(12.4)</b>	<b>(11.7)</b>	<b>4.0</b>	<b>4%</b>	<b>(22%)</b>	<b>6%</b>
Infrastructure Solutions	Sales Revenue	20.7	21.6	23.0	21.3	86.6	20.8	20.5	23.0	22.1	86.4	104.0	-	-	-
	<b>Core Operating Income</b>	<b>1.2</b>	<b>1.3</b>	<b>2.1</b>	<b>1.6</b>	<b>6.2</b>	<b>1.0</b>	<b>1.3</b>	<b>1.9</b>	<b>1.1</b>	<b>5.3</b>	<b>11.0</b>	<b>7%</b>	<b>6%</b>	<b>11%</b>
<b>Advanced Composites &amp; Shapes</b>	Sales Revenue	55.8	53.0	50.5	62.5	221.8	68.2	60.2	59.0	63.0	250.4	372.0	-	-	-
	<b>Core Operating Income</b>	<b>0.8</b>	<b>(1.4)</b>	<b>(4.0)</b>	<b>(6.9)</b>	<b>(11.5)</b>	<b>(0.8)</b>	<b>(1.4)</b>	<b>(3.6)</b>	<b>(5.7)</b>	<b>(11.5)</b>	<b>42.0</b>	<b>(5%)</b>	<b>(5%)</b>	<b>11%</b>
Engineering Shapes & Solution	Sales Revenue	31.5	34.1	29.4	33.5	128.4	37.9	32.4	32.8	36.0	139.1	166.0	-	-	-
	<b>Core Operating Income</b>	<b>2.2</b>	<b>0.5</b>	<b>(0.3)</b>	<b>1.5</b>	<b>3.8</b>	<b>2.5</b>	<b>1.7</b>	<b>0.9</b>	<b>2.7</b>	<b>7.8</b>	<b>19.0</b>	<b>3%</b>	<b>6%</b>	<b>11%</b>
Carbon Fiber · Composite	Sales Revenue	23.4	17.7	20.2	27.9	89.1	29.0	26.9	25.3	26.0	107.2	201.0	-	-	-
	<b>Core Operating Income</b>	<b>(0.3)</b>	<b>(1.1)</b>	<b>(2.2)</b>	<b>(6.6)</b>	<b>(10.2)</b>	<b>(2.4)</b>	<b>(2.3)</b>	<b>(3.6)</b>	<b>(6.7)</b>	<b>(15.0)</b>	<b>26.0</b>	<b>(11%)</b>	<b>(14%)</b>	<b>13%</b>

\* Breakdown figures of segment are approximation for reference purpose only.

# Number of Subsidiaries and Affiliates [Historical Data]

	(Number of companies)				
	FY2020	FY2021	FY2022	FY2023	FY2024
<b>Number of subsidiaries and affiliates</b>	666	625	593	552	<b>528</b>
<b>Companies in consolidation scope</b>	630	590	556	524	<b>504</b>
<b>Consolidated subsidiaries</b>	487	448	422	390	<b>373</b>
Japan	161	156	144	136	<b>130</b>
Overseas	326	292	278	254	<b>243</b>
Joint operation	4	4	3	4	<b>4</b>
Affiliates accounted for by the equity method	137	137	131	130	<b>127</b>
Companies for which the equity method does not apply as they are categorized as assets held for sale	2	1	-	-	<b>-</b>

\* The number of consolidated subsidiaries and affiliates for FY2024 of Pharma business is 25, which consist of 24 consolidated subsidiaries (4 domestic and 20 overseas) and 1 equity method affiliate.

# Overseas Sales Revenue, and Core Operating Income [Historical Data]

(Billions of Yen)

## Sales revenue and core operating income by geographic area based on location of consolidated subsidiaries

### Sales Revenue

Japan

Overseas

### Core Operating Income

Japan

Overseas

FY2020

FY2021

FY2022

FY2023

FY2024

3,257.5

3,976.9

4,634.5

4,387.2

**4,407.4**

2,109.5

2,526.5

2,862.6

2,553.7

**2,496.6**

1,148.0

1,450.4

1,771.9

1,833.5

**1,910.8**

174.7

272.3

325.6

208.1

**298.4**

92.5

159.7

197.3

18.7

**65.4**

82.2

112.6

128.3

189.4

**233.0**

## Overseas sales revenue based on location of customers

### Overseas Sales Revenue

1,464.9

1,860.6

2,315.3

2,199.7

**2,269.8**

45.0%

46.8%

50.0%

50.1%

**51.5%**

# Statements of Operations [Quarterly Data]

Exchange Rate (¥/\$)	139.6	145.6	146.1	149.9	145.3	158.2	146.7	154.2	151.2	152.6
Naphtha Price (¥/kl)	67,500	63,600	72,800	72,500	69,100	79,000	76,900	73,200	73,400	75,600

(Billions of Yen)

	FY2023					FY2024				
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total
<b>Sales Revenue</b>	1,061.2	1,088.7	1,095.2	1,142.1	4,387.2	1,129.4	1,112.7	1,089.4	1,075.9	4,407.4
<b>Core Operating Income *1</b>	50.8	68.8	64.3	24.2	208.1	82.6	89.8	74.8	51.2	298.4
Special Items	18.9	0.1	9.6	25.1	53.7	2.4	(38.1)	(22.0)	(44.0)	(101.7)
<b>Operating Income</b>	69.7	68.9	73.9	49.3	261.8	85.0	51.7	52.8	7.2	196.7
Financial Income/Expenses	(0.9)	(7.5)	(12.3)	(0.6)	(21.3)	(8.0)	(22.6)	2.6	(18.0)	(46.0)
(Dividend included above)	[4.6]	[0.1]	[1.3]	[0.2]	[6.2]	[2.4]	[0.1]	[1.1]	[0.0]	[3.6]
(Foreign Exchange Gain/Loss included above)	[4.5]	[2.7]	[(4.2)]	[4.5]	[7.5]	[4.2]	[(13.0)]	[10.9]	[(5.9)]	[(3.8)]
<b>Income(Loss) before Taxes</b>	68.8	61.4	61.6	48.7	240.5	77.0	29.1	55.4	(10.8)	150.7
Income Taxes	(13.0)	(23.1)	(11.4)	(14.6)	(62.1)	(20.7)	(14.2)	(19.8)	9.6	(45.1)
<b>Net Income</b>	55.8	38.3	50.2	34.1	178.4	56.3	14.9	35.6	(1.2)	105.6
<b>Net Income(Loss) Attributable to Owners of the Parent</b>	42.5	24.7	36.7	15.7	119.6	39.7	1.2	18.5	(14.4)	45.0
Net Income Attributable to Non-Controlling Interests	13.3	13.6	13.5	18.4	58.8	16.6	13.7	17.1	13.2	60.6
*1 Share of profit of associates and joint ventures included	2.7	1.5	2.3	1.1	7.6	1.9	1.2	4.0	1.0	8.1

# Special Items [Quarterly Data]

(Billions of Yen)

	FY2023					FY2024				
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total
<b>Total Special Items</b>	18.9	0.1	9.6	25.1	53.7	2.4	(38.1)	(22.0)	(44.0)	(101.7)
Gain on sales of shares of subsidiaries and associates	5.6	1.8	20.2	8.9	36.5	-	11.1	0.2	-	11.3
Gain on sale of property, plant and equipment	0.8	0.1	0.8	(0.1)	1.6	1.5	-	0.1	8.1	9.7
Impairment loss	(0.0)	(3.2)	(10.5)	(10.1)	(23.8)	(0.8)	(26.8)	(15.3)	(33.7)	(76.6)
Special retirement expenses	(0.2)	(0.2)	(0.8)	(0.8)	(2.0)	-	(17.9)	(0.4)	(3.8)	(22.1)
Loss on sale and disposal of fixed assets	(1.1)	(0.2)	(1.1)	(7.3)	(9.7)	(1.2)	(1.6)	(3.6)	(8.8)	(15.2)
Cancellation penalty	-	(0.0)	-	(0.3)	(0.3)	-	-	(3.3)	(0.2)	(3.5)
Loss on sales of shares of subsidiaries and associates	-	-	-	(0.1)	(0.1)	(0.4)	-	-	(2.8)	(3.2)
Others	13.8	1.8	1.0	34.9	51.5	3.3	(2.9)	0.3	(2.8)	(2.1)

# Capital Expenditure, Depreciation & Amortization, R&D Expenses, and Number of Employees by Business segment (FY2024 Actual)

(Billions of Yen)

	Capital Expenditure		Depreciation & Amortization		R&D Expenses		Number of Employees
	FY2023 Actual	FY2024 Actual	FY2023 Actual	FY2024 Actual	FY2023 Actual	FY2024 Actual	FY2024 Actual
<b>Total</b>	<b>283.9</b>	<b>339.2</b>	<b>275.4</b>	<b>275.9</b>	<b>121.6</b>	<b>123.9</b>	<b>63,258</b>
Specialty Materials	80.9	114.6	62.3	68.0	27.7	25.7	21,260
MMA & Derivatives	24.9	23.4	25.3	25.3	6.6	6.8	3,995
Basic Materials & Polymers	39.2	46.7	45.4	37.4	8.7	8.6	6,572
Others	7.5	4.2	13.8	13.1	11.2	11.3	7,179
Chemicals Business	152.5	188.9	146.8	143.8	54.2	52.4	39,006
Pharma	5.1	7.9	13.8	13.5	62.9	66.5	4,490
Industrial Gases	126.3	142.4	114.8	118.6	4.5	5.0	19,762
Group Business	131.4	150.3	128.6	132.1	67.4	71.5	24,252

# Capital Expenditure, Depreciation & Amortization, R&D Expenses by Business segment (FY2025 Forecast)

(Billions of Yen)


	Capital Expenditure		Depreciation & Amortization		R&D Expenses	
	FY2024 Actual	FY2025 Forecast	FY2024 Actual	FY2025 Forecast	FY2024 Actual	FY2025 Forecast
<b>Total</b>	<b>331.3</b>	<b>359.0</b>	<b>262.4</b>	<b>269.0</b>	<b>57.4</b>	<b>68.0</b>
Specialty Materials	114.6	131.0	68.0	71.0	25.7	33.0
MMA & Derivatives	23.4	24.0	25.3	26.0	6.8	7.0
Basic Materials & Polymers	46.7	35.0	37.4	34.0	8.6	9.0
Others	4.2	6.0	13.1	12.0	11.3	14.0
Chemicals Business	188.9	196.0	143.8	143.0	52.4	63.0
Industrial Gases	142.4	163.0	118.6	126.0	5.0	5.0

# Trends in Sales Revenue, Core Operating Income and EBITDA

## Sales Revenue

(Billions of yen)


After the transfer of Mitsubishi  
Tanabe Pharma Corporation \*1



## Core Operating Income · Ratio of Core Operating Income to Sales Revenue

(Billions of yen)


After the transfer of Mitsubishi  
Tanabe Pharma Corporation \*1




\*1 Following the resolution of the transfer of Mitsubishi Tanabe Pharma Corporation at MCG's annual shareholders' meeting, the Pharma business will be categorized as a discontinued operation and will be excluded from the scope of sales revenue and core operating income from continuing operations.

# Trends in Indicators for Profitability and Stability

## EPS · ROIC · ROE



## Net D/E ratio



\*1 EPS calculation excludes the profit of discontinued operations. Following the resolution of the transfer of Mitsubishi Tanabe Pharma Corporation at MCG's annual shareholders' meeting, the Pharma business will be categorized as a discontinued operation and will be excluded from the scope of earnings per share (EPS) from continuing operations. FY25 forecast and FY29 target are based on the above assumptions. EPS for the fiscal year ended March 2025 calculated with this exclusion is (1.7) yen.

\*2 FY29 performance targets for ROE are not disclosed.

# Calculation formula of indicators

Indicators	Calculation formula
ROIC	<p>NOPAT(*1) / Invested Capital (averages of beginning and end of fiscal years) (*2)</p> <p>(*1) NOPAT = (Core Operating Income - Share of profit of associates and joint ventures (included in Core Operating Income) X (1 - Tax rate) + Share of profit of associates and joint ventures (included in Core Operating Income) + Dividend Income</p> <p>(*2) Invested Capital = Total Equity + Interest-bearing debt</p>
ROE	<p>Net income attributable to owners of the parent / Equity attributable to owners of the parents (averages of beginning and end of fiscal years)</p>
Net D/E ratio	<p>Net interest-bearing debt(*3) / Equity attributable to owners of the parent</p> <p>(*3) Net interest-bearing debt = Interest-bearing debt - (cash and cash equivalents + cash reserves(*4))</p> <p>(*4) Cash reserves comprise certificates of deposits, securities, and other instruments other than cash equivalents that the Group holds to manage surplus funds.</p>

# References 2

# Pharma Segment, Status of Research and Development etc.

# Major Development Pipeline List

As of Apr. 25, 2025

Progress Update

Areas	Development code	Region / Country	Indications/Description	P1	P2	P3	Filed	Approved
Central Nervous System	ND0612	Global	Parkinson's disease					
	MT-3921	Global	Spinal cord injury					
	MT-0551	Japan <sup>*1</sup>	Myasthenia gravis					
Immuno-inflammation	MT-7117	Global	Erythropoietic protoporphyria (EPP) X-linked protoporphyria (XLP)					
		Global	Systemic sclerosis					
	MT-0551	Japan <sup>*1</sup>	IgG4-related disease					
		Japan	Systemic sclerosis					
Oncology	MT-2111	Japan	Relapsed/Refractory Diffuse Large B-cell Lymphoma (Monotherapy)					
		Japan <sup>*2</sup>	Relapsed/Refractory Diffuse Large B-cell Lymphoma (with rituximab)					

<sup>\*1</sup> Co-development with Amgen

<sup>\*2</sup> Co-development with ADC Therapeutics

# Launch Plan for Major Development Pipeline

	FY2024	FY2025	FY2026 and beyond
Central Nervous System		<b>ND0612</b> Parkinson's disease (Global)	<b>MT-0551</b> Myasthenia gravis (Japan *1)
Immuno-inflammation		<b>MT-0551</b> IgG4-related disease (Japan*1)	<b>MT-7117</b> EPP, XLP (Global)
Diabetes and Kidney	<b>CANAGLU OD tablets</b> Type 2 diabetes mellitus, Chronic kidney disease complicated with type 2 diabetes mellitus*2 (Japan)	<b>CANALIA combination OD tablets</b> Type 2 diabetes mellitus*3 (Japan)	
Oncology			<b>MT-2111</b> Relapsed/Refractory Diffuse Large B-cell Lymphoma (Monotherapy) (Japan)
			<b>MT-2111</b> Relapsed/Refractory Diffuse Large B-cell Lymphoma (with rituximab) (Japan*4)


\*1 Co-development with Amgen

\*2 Chronic kidney disease complicated with type 2 diabetes mellitus, excluding patients with end-stage renal disease or undergoing dialysis

\*3 Type 2 diabetes mellitus

However, The drug product should be used only in patients for whom treatment with concomitant teneligliptin hydrobromide hydrate and canagliflozin hydrate is considered appropriate

\*4 Co-development with ADC Therapeutics

 : Global (US launch year)     : Japan     : Launched

# Long-Acting GIP/GLP-1 Receptor Agonist “Zepbound”

- Released in Japan on April 11, 2025

- Indication: Obesity disease\*1
- Six dose standards of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg
- Mitsubishi Tanabe Pharma Corporation (MTPC) is responsible for sales and distribution of Zepbound and Eli Lilly Japan and MTPC will jointly provide information



\*1 Zepbound’s approved indication is as below:

“Obesity disease

However, its use is limited to people with any of hypertension, dyslipidemia, or type 2 diabetes mellitus and do not adequately respond to diet or exercise therapy and meet any of the following conditions:

- BMI of  $\geq 27$  kg/m<sup>2</sup> in the presence of at least two obesity-related health conditions
- BMI of  $\geq 35$  kg/m<sup>2</sup>.”

# Pharmaceuticals Business: Statements of Operations (FY2024 Actual)

(Billions of Yen)

	FY2023	FY2024	Difference	%
<b>Revenue</b>	437.4	460.4	23.1	5.3%
Domestic	310.2	319.8	9.7	3.1%
Overseas	127.2	140.6	13.4	10.5%
Overseas sales ratio	29.1%	30.5%		
<b>Cost of sales</b>	210.7	219.9	9.2	4.4%
Sales cost ratio	48.2%	47.8%		
<b>Gross profit</b>	226.7	240.5	13.9	6.1%
<b>SG&amp;A expenses, etc.</b>	170.4	175.3	4.9	2.9%
R&D expenses	63.0	66.5	3.5	5.6%
<b>Core operating profit</b>	56.2	65.2	9.0	16.0%
Non-recurring items	12.7	(13.6)	(26.3)	
<b>Operating profit</b>	68.9	51.6	(17.3)	(25.1%)
<b>Net profit attributable to owners of the Company</b>	56.4	23.2	(33.2)	(58.8%)

Effect of fluctuations in exchange rate for FY2024: Revenue increased by ¥5.5 bn. and core operating profit increased by ¥5.0 bn.

# Pharmaceuticals: Details of Revenue (FY2024 Actual)

(Billions of Yen)

	FY2023	FY2024	Difference	%
<b>Domestic ethical drugs</b>	300.8	<b>310.6</b>	<b>9.8</b>	3.2%
<b>Priority and New products</b>	171.7	<b>163.5</b>	<b>(8.2)</b>	<b>(4.8%)</b>
Stelara	65.3	<b>56.7</b>	<b>(8.6)</b>	<b>(13.2%)</b>
Simponi	43.3	<b>41.4</b>	<b>(2.0)</b>	<b>(4.5%)</b>
Tenelia	12.0	<b>12.4</b>	<b>0.4</b>	3.3%
Canaglu	11.8	<b>11.7</b>	<b>(0.1)</b>	<b>(1.0%)</b>
Canalia	10.8	<b>7.8</b>	<b>(2.9)</b>	<b>(27.2%)</b>
Vafseo	2.2	<b>2.2</b>	<b>(0.0)</b>	<b>(0.2%)</b>
Uplizna	6.1	<b>10.4</b>	<b>4.3</b>	71.6%
Rupafin	9.3	<b>9.3</b>	<b>0.0</b>	0.1%
Dysval	5.4	<b>5.3</b>	<b>(0.2)</b>	<b>(3.0%)</b>
Radicut	5.5	<b>6.3</b>	<b>0.8</b>	15.5%
<b>Vaccines</b>	34.3	<b>47.6</b>	<b>13.2</b>	38.5%
Influenza vaccine	10.6	<b>13.7</b>	<b>3.1</b>	29.2%
GOBIK	1.2	<b>15.8</b>	<b>14.6</b>	1,187.6%
Tetrabik	8.8	<b>3.1</b>	<b>(5.6)</b>	<b>(64.4%)</b>
JEBIK V	3.3	<b>3.4</b>	<b>0.1</b>	1.7%
Mearubik	5.0	<b>6.1</b>	<b>1.2</b>	23.3%
Varicella vaccine	4.1	<b>4.0</b>	<b>(0.2)</b>	<b>(4.0%)</b>
<b>Long-listed drugs, etc.</b>	94.8	<b>99.5</b>	<b>4.7</b>	5.0%
Remicade	29.7	<b>23.3</b>	<b>(6.4)</b>	<b>(21.6%)</b>
<b>Overseas ethical drugs</b>	111.7	<b>128.6</b>	<b>16.9</b>	15.2%
<b>Radicava</b>	79.2	<b>100.3</b>	<b>21.0</b>	26.5%
<b>Royalty revenue, etc.</b>	16.9	<b>12.9</b>	<b>(3.9)</b>	<b>(23.3%)</b>
<b>Royalty from INVOKANA</b>	6.6	<b>7.1</b>	<b>0.4</b>	6.7%
<b>Royalty from GILENYA</b>	5.4	<b>3.8</b>	<b>(1.5)</b>	<b>(28.6%)</b>

Mounjaro (based on Japanese NHI prices) : ¥40.7bn. (1Q: ¥4.8bn., 2Q: ¥8.1bn., 3Q: ¥12.4bn., 4Q: ¥15.4bn.)

For the purpose of this notice, “statements” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Mitsubishi Chemical Group.

The forward-looking statements are based largely on company expectations and information available as of the date hereof, and are subject to risks and uncertainties, which may be beyond company control.

The Group is engaged in a very diverse range of businesses, including various functional products, MMA, petrochemicals, carbon products, industrial gases, and pharmaceuticals, and its performance may be affected by domestic and international demand, exchange rates, prices and procurement volumes of raw materials and fuels such as naphtha and crude oil, product market trends, speed of technological innovation, NHI price revisions, product liability, litigation, legal regulations, etc. The Company's business performance may be affected by such factors. However, factors that may affect our business performance are not limited to these factors.

It contains information about pharmaceuticals including products under development, but is not intended for advertising or medical advice.